Record Q2 revenue and profit exceeded guidance, driven by strong MACI and Burn Care growth. Full-year guidance was raised, a $200 million share repurchase was announced, and significant progress was made on U.K. expansion and clinical initiatives.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.